ArticleFrontiers in endocrinology2026
Modulation of cell migration and invasion of thyroid cancer cells using miRNA-enriched extracellular vesicles.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracellular vesicles (EVs) have been investigated as promising vehicles for delivering drugs and microRNAs (miRNAs) in distinct types of cancer. However, their use as a delivery system in papillary thyroid carcinoma (PTC) remains underexplored. PTC is the most prevalent subtype of thyroid cancer, and despite its good prognosis, a fraction of the cases evolve into aggressive and fatal forms. Here, we investigated whether non-tumor thyroid cells can be engineered to produce EVs-enriched with tumor suppressor miRNAs that could be delivered to PTC cells. Methods: EVs from NThy-ORI cells transfected with Results: Non-tumor thyroid NThy-ORI cells overexpressing Conclusions: These findings suggest the potential of thyroid-derived EVs as a biologically relevant and promising system for delivering tumor suppressor miRNAs, opening new opportunities to explore this approach as a therapeutic strategy for PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.